AEA-D8

Description

Arachidonoyl ethanolamide-d₈ (AEA-8) contains eight deuterium atoms at the 5, 6, 8, 9, 11, 12, 14, and 15 positions. It is intended for use as an internal standard for the quantification of AEA by GC- or LC-mass spectrometry. AEA is the ethanolamine amide of arachidonic acid, first isolated from porcine brain.¹ It is an endogenous cannabinoid neurotransmitter that binds to both CB₁ and CB₂ receptors.² AEA inhibits the specific binding of [³H]-HU-243 to synaptosomal membranes with a K_i value of 52 nM, compared to 46 nM for Δ⁹-THC.¹

Uses

Anandamide-d8 is a deuterated labeled Anandamide[1]. Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis[2][3][4][5][6].

Definition

ChEBI: Anandamide is an N-acylethanolamine 20:4 resulting from the formal condensation of carboxy group of arachidonic acid with the amino group of ethanolamine. It has a role as a neurotransmitter, a vasodilator agent and a human blood serum metabolite. It is an endocannabinoid and a N-acylethanolamine 20:4. It is functionally related to an arachidonic acid.

in vivo

References

1. Devane, W.A., Hanus, L., Breuer, A., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258(5090),1946-1949(1992).
2. Felder, C.C., Briley, E.M., Axelrod, J., et al. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction Proc. Natl. Acad. Sci. USA 90(16),7656-7660(1993).